NYR.AX ASX
Nyrada Inc.
1W: +0.0%
1M: -27.8%
3M: +23.8%
YTD: -35.8%
1Y: +100.0%
3Y: +1900.0%
5Y: +85.7%
A$0.51 ($0.35)
+0.01 (+2.00%)
Weekly Expected Move ±13.4%
A$0
A$0
A$1
A$1
A$1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market CapA$126.5M ($88.0M)
52W Range0.29-1.44
Volume176,651
Avg Volume307,557
Beta0.94
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJames Bonnar
Employees4,000
SectorHealthcare
IndustryBiotechnology
IPO Date2020-01-15
Websitenyrada.com
Salesforce Tower, Sydney Place
Sydney, NSW 2000
AU
Sydney, NSW 2000
AU
61 2 9498 3390
About Nyrada Inc.
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Latest News
No recent news
Recent Insider Trades
No insider trades found